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T
he definition of clinical and laboratory
features affecting prognosis is one of the
main aims of statistical analysis on a
large series of patients. The most popular meth-
ods applied for this purpose are univariate
analysis and Cox’s proportional hazard model.1
Cluster analysis methods,2,3 using a mathe-
matical algorithm, are particularly appropriate
for detecting subgroups of observations with
similar features in relatively large series. This
approach is useful since it enables us to define
different disease entities, different etiologies or
different therapeutic or prognostic outcomes
on an adequate series of patients. The advan-
tage to these methods lies in their power to
define subgroups involving a duality between
variables and subjects. The aim of this work
was to analyze retrospectively 160 AML patients
referred to the Institute of Hematology of Fer-
rara, using cluster analysis to delineate sub-
groups of patients with particular features and
different prognoses. 
Patients and methods
One hundred sixty de novo AML patients,
aged 14-86 years, consecutively referred to the
Institute of Hematology of Ferrara between
January, 1979 and April, 1992 were retrospec-
tively studied. At diagnosis all patients, classi-
Correspondence: Dr. Gian Matteo Rigolin, Institute of Hematology, University of Ferrara, via Savonarola 9, 44100 Ferrara, Italy. Fax: interna-
tional +39.532.212142.
Acknowledgments: this work was supported by MURST (60%) and CNR Rome.
Received February 2, 1994; accepted April 7, 1994.
STUDY OF PROGNOSIS IN ACUTE MYELOID LEUKEMIAS (AML) BY
CLUSTER ANALYSIS
Gian Matteo Rigolin, Franca Fagioli, Romedio Spanedda, Gianluigi Scapoli, Francesco Lanza,
Antonio Cuneo, Paolo Tomasi, Gianluigi Castoldi
Institute of Hematology, University of Ferrara, Italy
original papers
Haematologica 1994; 79:233-240
ABSTRACT
Background. Cluster analysis is particularly effective in detecting homogeneous subgroups
among large series of observations. We applied this relatively uncommon approach to the study
of prognosis in 137 patients affected by acute myeloid leukemia (AML).
Methods and Results. Employing simple presentation parameters (age, WBC, splenomegaly,
hepatomegaly) we used cluster analysis to define 3 groups with different overall survival
(p=0.0019). This classification was obtained following a rescaling of the variables and principal
component analysis. Validation was performed through random definition of a control group.
With the same variables, univariate analysis demonstrated age was the only prognostic factor,
while Cox’s model was not significant.
Conclusions. In our series cluster analysis allowed a better definition of prognosis than Cox’s
analysis. Since the 3 groups are well identifiable, each patient can be rapidly classified and his
allocation confirmed by discriminant functions. For cluster 2 we were able to project a possible
myelodysplastic evolution, while cluster 3 was more frequently associated with a monocytic blas-
tic component. We think that cluster analysis deserves consideration as an alternative statistical
approach in the analysis of large series of data; its usefulness lies in its power to define homoge-
neous prognostic or biologic subgroups and to elaborate further  hypotheses for new studies.
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fied in accordance with FAB criteria,4,5 under-
went clinical and laboratory studies that includ-
ed physical examination, hemoglobin, white
blood cell (with differential) and platelet deter-
minations, evaluation of kidney, liver and heart
functions. Two protocols, described elsewhere,6
were applied for induction: the first regimen
consisted of one course of DAT3/7 (daunoru-
bicin, cytosine arabinoside and thioguanine)
followed by 3 DAT1/5 each after a 15-day inter-
val; the second consisted of 2 VAE (vindesine,
cytosine arabinoside and etoposide) alternating
DAT3/7 and DAT1/5 after a 2-week interval.
Conventional dosages were reduced in the pres-
ence of kidney, heart or liver impairment or
advanced age. In some patients daunorubicin
was substituted by epirubicin or idarubicin or
mitoxantrone. Patients in complete remission
at the end of induction received monthly alter-
nating courses of AT1/5, AT1/5 or VAE, DAT1/5
as maintenance therapy. Treatment was stopped
after a 2-year event-free period. Patients with
low performance status received low-dose cyto-
sine arabinoside induction and maintenance
regimens. Eleven patients, aged 18-34, under-
went bone marrow transplantation.
Statistical analysis
Overall survival (OS) and relapse-free sur-
vival (RFS) were computed according to the
Kaplan-Meier technique:7 OS was determined
from the time of diagnosis, while RFS was com-
puted from the time of first bone marrow aspi-
ration in complete remission (CR). Patients
who underwent bone marrow transplantation
did not drop out of the study. Survival and
remission durations were compared by the log-
rank test.8 Cox’s hazard proportional model
(Maximum Log-Likelihood Estimate) was used
to determine multifactorial effects of presenta-
tion parameters on survival and CR durations.9
The chi-square test was used throughout; k-
means Hartgan’s algorithm10 was used in cluster
analysis. Data were rescaled using a rank trans-
formation (high tie). Principal component
analysis was applied in order to extract the real
variables describing our group of patients; this
vectorial analysis procedure allows exclusion of
those variables whose weight is not relevant to
the definition of the population. Validation was
obtained with a cohort of subjects after random
division of the patients into two groups: one
(70% of subjects) for cluster definition, the
other (30% of patients) as control group. The
grouped and ungrouped patients were then
classified with discriminant analysis to verify
the goodness of cluster definition. At the end of
Cox’s analysis, the patients were divided into
three groups according to the numeric value of
the prognostic score. These groups were then
compared with a log-rank test for their prog-
nostic impact.
The SPSS statistical package was used for
elaborating the data. Data were analyzed in
May, 1993.
Results
Of the 160 patients considered for this study,
137 were valuable for statistical analysis; 13 who
received low-dose cytosine arabinoside induc-
tion treatment were excluded because this regi-
men was not comparable with that applied to
the great majority of patients; 4 cases were
excluded for major protocol violations, 4 for
inadequate follow-up documentation, 2 for
refusal of treatment.
Table 1 summarizes the principal features of
the 137 patients at presentation. Five-year OS
of the 137 patients was 5.7% (standard error,
SE 2.3%), with a median OS of 3 months.
Forty-six (33.6%) patients achieved CR with a
5-year RFS of 20.4% (SE 7.0%) and a median
RFS of 14 months. The impact of age on sur-
vival was studied by stratifying patients in three
groups (≤35 years; 36-70; ≥70): the 5-year OS
of the three groups was, respectively, 0%, 8.7%
(SE 4.6%), 3.4% (SE 2.7%)(p=0.015), while
median OS was 11, 5 and 2 months, respectively. 
The 5-year OS of patients who achieved and
those who did not achieve CR were, respectively,
17.5% (SE 6%) vs 0% (p<0.0001) and median
OS was 16 vs 2 months. No other factors affect-
ed OS or RFS in univariate analysis. Following
principal component analysis, four variables
(age at diagnosis, splenomegaly, hepatomegaly,
white blood cell count) were tested in Cox’s
proportional hazard model for their impact on
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survival and RFS: Cox’s regression, considering
all the four variables together, was not signifi-
cant for OS (chi-square 9.03, 4 df; p=0.07),
while the model was significant (chi-square
12.8, p=0.015, 4 df) regarding RFS. Hartgan’s
algorithm, with the same variables tested in
Cox’s analysis, was used to perform cluster
analysis. We identified 3 different groups, the
clinical and laboratory features of which are
presented in Table 2 and Figure 1. The 3 groups
were compared for OS (Figure 2): the 5-year OS
was, respectively, 4.9% (SE 3.0%), 0%, 6.4%
(SE 4.0%), with a median OS of 6, 1 and 4
months, respectively (p=0.0019). Five-year RFS
for the three clusters was 13.6% (SE 7.7%), 0%,
24 (SE 14%), respectively, while median RFS
was 8, 23 and 18 months (p=0.010: Tarone-
Ware statistic). To validate cluster analysis all
patients were divided by means of a random
choice procedure into two groups: one (99 pts.)
for cluster determination (Table 3; Figure 3),
the other to verify by discriminant analysis the
distribution of the ungrouped subjects in the
predefined clusters. Correct allocation of
patients was attained in 85% of cases (Figure
4). The OSs of the 3 predefined groups were
significantly different (p=0.003), and the three
classes of patients obtained considering prog-
nostic score values were also significantly differ-
ent (p=0.03). A comparison between the cluster
analysis results and Cox’s analysis was made by
defining 3 groups on the basis of the prognostic
score and observing the outcomes of the two
approaches in both univariate analysis and in
Cox’s model (categorical variables). Within
clusters, stepwise Cox’s analysis demonstrated a
prognostic impact for splenomegaly in cluster 1
(chi-square 5.246, 1 df, p=0.025), and for
hepatomegaly in cluster 3 (chi-square=5.071, 1
df, p=0.023).
Prognosis in acute myeloid leukemias
n° pts 137
M/F 75/62
median age (yr) 62 (14-86)
splenomegaly (n° pts) 55 (40.1%)
hepatomegaly (n° pts) 80 (58.4%)
Hb (median) g/dL 9.0 (4.4-15.7)
WBC 109/L 7.3 (0.2-371.3)
Plts 109/L 72 (7-658)
M1 n° pts (%) 12 (8.6%)
M2 n° pts (%) 32 (22.9%)
M3 n° pts (%) 13 (9.3%)
M4 n° pts (%) 43 (30.9%) 
M5 n° pts (%) 29 (20.7%)
M6 n° pts (%) 6 (4.3%)
M7 n° pts (%) 2 (1.4%)
CR n° pts (%) 46 (33.6%)
induction deaths pts (%) 49 (35.7%)
relapse n° pts (%) 31 (67.4%)
mean follow-up (months) 12 (1-128)
Table 1. Clinical-laboratory features at presentation.
cluster 1 2 3
n° pts 60 41 36
M/F 30/30 25/16 20/16
M1 n° pts (%)* 6 (10%) 4 (9.8%) 2 (5.6%)
M2 n° pts (%)* 15 (25%) 9 (22%) 7 (19.4%)
M3 n° pts (%)* 8 (13.3%) 2 (4.9%) 2 (5.6%)
M4 n° pts (%)* 21 (35%) 12 (29.3%) 13 (36.1%)
M5 n° pts (%)* 9 (15%) 14 (17.7%) 10 (27.8%)
M6 n° pts (%)* 0 5 (12.3%) 1 (2.8%)
M7 n° pts (%)* 1 (1.7%) 0 1 (2.8%)
induction deaths (%)° 11 (18.5%) 21 (50.2%) 11 (30.5%)
5-yr OS (SE)# 4.9 (3.0%) 0% 6.4 (4.0%)
pts alive (%) 5 (18.3%) 1 (2.4%) 2 (5.6%)
CR n° pts (%)^ 29 (48.3%) 3 (7.3%) 12 (33.3%)
*p=ns; °p=0.0023; #p=0.0019; ^ p=0.0008
Table 2. Clinical-laboratory aspects of the 3 cluster analysis groups.
236
Discussion
The definition of prognostic groups in a large
series of patients is the main aim of statistical
analysis. The most popular methods applied for
G. M. Rigolin et al.
Figure 1. Box plots of the 4 classifying variables in the three clusters of patients.
Figure 2. Cluster analysis and survival Log-rank test statistic: overall p=0.0019; cluster 1 vs cluster 2, p=0.0008; cluster 1 vs
cluster 3 p=0.071;  cluster 2 vs cluster 3, p=0.0018.
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this purpose are univariate analysis and multi-
variate analysis via Cox’s proportional hazard
model. Two limitations to this approach are the
heterogeneity of the population analyzed and
the observation that a parameter that could be
prognostically important for one group of
patients might not be decisive in another.
Cluster analysis methods, which consider a
duality between variables and subjects, are par-
ticularly effective in the definition of distinct
subgroups of patients with similar features; in
this sense they are more flexible than other
methods. These groups may represent different
diseases, different etiopathologic mechanisms,
different probabilities of response to therapies
or different prognoses.
As recently reviewed in the literature, very
few studies have applied cluster analysis as a
statistical method. In particular, to our knowl-
edge this approach had never been used in the
study of AML prognosis. Our application could
be a model for an alternative statistical approach
to subgrouping AML patients with a view to
defining prognosis or other biological features.
Using this relatively uncommon approach we
were able to distinguish 3 groups of patients
with different prognostic outcomes and CR
rates on the basis of 4 simple variables. An
interesting aspect of our analysis is the compar-
ison of results obtained using conventional
methods (univariate analysis and Cox’s hazard
model) with those using cluster analysis. Age at
diagnosis was delineated as the only variable
affecting survival in univariate analysis, while in
Cox’s model all four variables together were not
significant. 
These results in our opinion suggest that,
when studying prognosis or other biological
aspects in a large series of patients, cluster
analysis could be a very useful tool for analyz-
ing data in order to separate distinct groups of
subjects with similar features. Besides its prog-
nostic impact, this and other possible classifica-
tions could be used to formulate operative
hypotheses for new studies.
In particular, from our analysis of hematolog-
ical parameters in the 3 groups studied we can
hypothesize that group 2, with its lower median
white blood cell count, tendency to low hemo-
globin levels, lower mean peripheral blast cell
percentage (40% vs 60%) and five M6 patients,
represents a cluster with a high percentage of
Prognosis in acute myeloid leukemias
Figure 3.  Cluster analysis and  survival Log-rank test statistic in the 99 randomly selected patients: overall p=0.007; cluster 1
vs cluster 2, p=0.0001; cluster 1 vs cluster 3, p=0.11; cluster 2 vs cluster 3, p=0.0018.  
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patients with dysplastic hematopoiesis. In fact,
some of these parameters tend to fulfill criteria
for the presence of dysplastic hematopoiesis.11
On the other hand, group 3 (characterized by
hepatosplenomegaly) could be considered a
subset of patients with a higher incidence of
monocyte lineage involvement. This cluster
does indeed show a higher incidence of M4 and
M5, in which organomegaly is often associated
with a peculiar pattern of presentation. This
cluster is also characterized by a higher WBC
count, which was correlated with a loss of HLA
class I antigens.12
The definition of more homogeneous sub-
groups could also represent a useful step in the
development of further analyses on subsets of
patients.13 Within clusters it is also possible to
identify new prognostic implications. In clus-
ters 1 and 3 Cox’s analysis demonstrated that
splenomegaly and hepatomegaly, respectively,
had further prognostic impact.
Another possible advantage to this approach
is the fact that it utilizes simple variables includ-
ed in the routine approach to all patients. Each
cluster is well identifiable for its clinical and
laboratory features; moreover, using discrimi-
nant functions, we can predict the probability
that new patients will belong to one or other
group, thus facilitating the definition of differ-
ent therapeutic strategies. The patients in the
control group were in fact correctly classified in
85% of cases.
We also decided to perform cluster analysis
with age at diagnosis as the only subgrouping
variable, to test if this alone could justify the
statistical significance of our results. The 3
groups resulting from this approach were char-
acterized by completely different median ages
from those obtained in the previous cluster
analysis approach (Table 4). The OSs of the cor-
responding 3 groups differ (p=0.015 vs p=
G. M. Rigolin et al.
cluster 1 2 3
n° pts 23 73 41
median age 24 (14-42) 52 (43-59) 69 (61-84)
5-yr OS (SE)* 0 3.4% (2.8%) 7.8% (4.3%)
* p=0.015
Table 4. Cluster analysis with age at diagnosis as only sub-
grouping variable.
cluster 1 2 3
n° pts 15 31 53
M/F 4/11 21/10 30/23
age (median) 57 (19-73) 73.5 (59-86) 54.1 (16-86)
Hb g/dL 7.6 (6.5-12) 9.1 (6-14) 9.0 (5.2-13.7)
WBC 109/L 51 (6-371) 2.7 (0.7-50) 6.1 (0.2-122)
Blasts % 78.2 (35-95) 40 (5-59) 48 (10-67)
Plt 109/L 58 (20-243) 50 (9-227) 81 (17.395)
hepatomegaly n° pts 13 (87%) 30 (93%) 12 (23%)
splenomegaly n° pts 13 (87%) 14 (52%) 9 (17%)
M1 n° pts (%)* 2 (13.3%) 4 (12.9%) 3 (5.7%)
M2 n° pts (%)* 2 (13.3%) 5 (16.1%) 13 (24.5%)
M3 n° pts (%)* 1 (6.7%) 1 (3.2%) 6 (11.3%)
M4 n° pts (%)* 6 (40.7%) 11 (35.5%) 19 (35.8%)
M5 n° pts (%)* 3 (20%) 6 (19.4%) 10 (18.9%)
M6 n° pts (%)* 0 6 (19.4%) 1 (1.9%)
M7 n° pts (%)* 1 (6.7%) 0 1 (1.9%)
induction deaths (%)^ 2 (13.3%) 16 (51.6%) 15 (28.3%)
5-yr OS (SE)§ 13.3 (8%) 0% 3.3 (2%)
pts alive (%) 1 (6.7%) 0 4 (7.5%)
CR n° pts (%)° 7 (46.7%) 2 (6.5%) 20 (37.7%)
relapses 6 1 13
*p=ns; ^p=0.01; °p=0.001; §p=0.007
Table 3. Clinical-laboratory features of the 3 clusters obtained with 99 (randomly selected) patients.
0.0019 for the previous analysis), indicating the
importance of the other parameters in this sub-
grouping and an even higher statistical signifi-
cance for the multi-variable approach. The 3
groups defined by cluster analysis using age at
diagnosis as the only variable are very similar to
those obtained with age stratification in uni-
variate analysis. These observations confirm the
validity of cluster analysis in elaborating data
and demonstrate its usefulness in analyzing the
prognostic impact of single variables as well.
The CR rate and the OS of this series of
patients might appear dissimilar from those
reported in international studies.14-16 We have to
stress that we decided to enroll patients over 65
years old who are usually excluded in interna-
tional survival reports. This decision had two
motivations: first, to define the real leukemic
population referred to our Institute with its OS
and RFS and, second, to demonstrate the use-
fulness of cluster analysis in subgrouping obser-
vations. Our series of patients was characterized
by a higher median age (62 years) than that of
other reports: 56.4% of our patients were over
60, 75% over 50 years of age. Only 46 patients
achieved CR but 5-year RFS of this group was
exactly within international standards. When
considering survival reports, one of the main
problems is the comparability of the patients
involved. 
In conclusion, we propose cluster analysis as a
possible and very powerful method for analyz-
ing a large series of observations. This approach,
which defines groups of subjects with similar
features, could be very useful for examining
data with a view to defining prognostic groups
or other clinical-biological implications.
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